Home Compare EUZ.DE vs HIK.L
Stock Comparison · Single-driver result

Eckert & Ziegler vs Hikma Pharmaceuticals: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Eckert & Ziegler SE carrying a narrow edge on profitability. Hikma Pharmaceuticals still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The comparison is mainly decided in profitability, with the rest of the profile carrying less weight.

Trajectory Similarity
0.72
Similar
Peer-set rank: #3
within Eckert & Ziegler SE's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair sits on a clearly comparable long-term path, though it is not a near-twin match.

The match is driven mainly by capital structure and revenue growth trajectory.

Similarity drivers
capital structurerevenue growth trajectory
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
EUZ.DE
Eckert & Ziegler SE
56
Peer-Score
Signal qualityHigh
vs
HIK.L
Hikma Pharmaceuticals PLC
53
Peer-Score
Signal qualityMedium

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in profitability.

Dimension spread: EUZ.DE vs HIK.L Profitability 78 39 Stability 11 32 Valuation 69 87 Growth 50 44 EUZ.DE HIK.L
Gap Ranking
#1 Profitability +39
#2 Stability +21
#3 Valuation +18
#4 Growth +6
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for EUZ.DE and HIK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer EUZ.DEHIK.L Relative valuation Structural strength

The setup splits cleanly: structure favours Eckert & Ziegler SE, while the price setup favours Hikma Pharmaceuticals PLC.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Eckert & Ziegler SE ranks near the top of the group on profitability; Hikma Pharmaceuticals PLC sits in the weaker half.
Stability
Neither side looks especially strong on stability, though Hikma Pharmaceuticals PLC still ranks somewhat higher.
Profitability — Dominant Gap
EUZ.DE
78
HIK.L
39
Gap+39in favour of EUZ.DE

Capital efficiency adds support, with a 14.9-point ROIC advantage.

What keeps the gap from being one-sided

A meaningful counterforce remains in stability, which keeps the comparison from looking completely one-sided.

What this means for the comparison

The main read on profitability is clearer than the broader score gap.

Explore full peer positioning in AssetNext

Break down the EUZ.DE vs HIK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how EUZ.DE and HIK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.